Studienzentrum Dr. Schwarz — Clinical Trial Site

9 Registered trials

3 Currently recruiting

Organisation

Studienzentrum Dr. Schwarz

Location

Langenau, Germany

Identifier

ORL-000001625

Address

Bismarkstraße 49, 89129, Germany

Departments

Dermatologie und Allergologie
Dermatology and Allergology
N/A
NA
Private Practice
Studienzentrum Dr. Schwarz

Clinical trials at this site (9)

Search interface

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-505121-14-00 Moderate to Severe Plaque Psoriasis 5 2024-01-18
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-experienced Participants with Active Psoriatic Arthritis Recruiting

2024-517284-23-00 Active Psoriatic Arthritis 5 2025-04-23
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Adaptive Phase 3 Study to Evaluate the Efficacy and Safety of Sinecatechins (De… Recruiting

2022-502811-12-00 Actinic Keratosis (AK) of the Scalp and/or the Face. 5 2024-09-04
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended

2023-509239-19-00 Active Psoriatic Arthritis 5 2025-04-03
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513208-32-00 Chronic Spontaneous Urticaria 5 2024-12-16
Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended

2023-507204-31-00 Hidradenitis Suppurativa 5 2024-07-26
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of… Ended

2024-517814-13-00 Moderate to Severe Atopic Dermatitis 4 2025-04-30
This is a clinical trial (study), to be conducted in several clinical sites worldwide, of an oral study drug which will be investigated in a… Ended

2023-503957-36-00 Moderate-to-Severe pruritus in adult subjects with nota 10 2023-12-04
A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoria… Ended

2023-508992-35-00 Plaque Psoriasis 4